Camizestrant for hormone-positive, HER2-negative early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older at screening.
- Your breast cancer is ER-positive and HER2-negative and was early-stage, removed with surgery.
- You finished local treatment (usually surgery, with or without radiation), and you may have had chemo.
- You’ve completed at least 2 years (up to about 5.25 years) of standard hormone therapy after treatment, with or without a CDK4/6 inhibitor.
- Your general health is good enough (ECOG 0–1) and your blood and organ tests are adequate.
- Your heart rhythm and heart function meet study safety thresholds (including certain QTc and ejection fraction limits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (camizestrant and ribociclib) for advanced breast cancer that is hormone-receptor-positive and HER2-negative. The study aims to see if this combination helps patients whose cancer cannot be surgically removed or treated with radiation alone.
This trial tests an investigational drug called camizestrant, which may block estrogen signals that help endometrial cancer grow. It is given before surgery to see if it can shrink tumors and help people with early-stage, ER-positive endometrial cancer.
This trial tests two experimental drugs—camizestrant and atirmociclib—for women with advanced ER-positive breast cancer that has worsened after prior treatment. The goal is to see if the combination is safe and tolerable.
This trial tests a combination of two drugs, camizestrant and ribociclib, for people with a certain type of advanced breast cancer (HR+/HER2-). It is for those whose cancer has grown or spread despite previous hormone therapy. The goal is to see if this new combination can help control the cancer.
This trial compares a new medicine, elacestrant, to the usual hormone therapy for people with early-stage breast cancer that is hormone receptor-positive and HER2-negative, and who have a high chance of it coming back. The goal is to see if elacestrant works better at preventing the cancer from returning.
This trial tests whether elacestrant can help stop or delay breast cancer coming back in people whose blood test shows “ctDNA relapse” after early breast cancer treatment. It’s meant for hormone receptor–positive, HER2-negative breast cancer patients who are already taking hormone (endocrine) therapy and have no visible spread on scans.
Hear when a new Breast Cancer, Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.